Analyst Price Target is $15.00
▲ +1,400.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cortexyme in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 1,400.00% upside from the last price of $1.00.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Cortexyme. This rating changed within the last month from a Hold consensus rating.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.